Zevra Therapeutics Faces Investor Investigation After Stock Plunge

Zevra Therapeutics (NASDAQ: ZVRA) is facing an investigation by law firm Levi & Korsinsky after its stock price plummeted approximately 24% in pre-market trading on July 24, 2026. The sharp decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa.

The CHMP's decision concerned arimoclomol's use for Niemann-Pick disease type C. Reports indicated the selloff represented the stock's worst single-day percentage loss in over five years. The investigation will examine whether investors who suffered losses may have potential securities law claims related to the market reaction following the regulatory announcement.

Following the negative opinion, Zevra Therapeutics stated its intention to request a re-examination of the decision. The company also confirmed it would continue providing arimoclomol to eligible patients through its global Expanded Access Program pending further regulatory review.

Levi & Korsinsky is encouraging Zevra Therapeutics investors who incurred losses to come forward as the investigation proceeds. The firm specializes in representing shareholders in securities class actions and is examining whether company statements regarding arimoclomol and its regulatory outlook were potentially misleading prior to the CHMP's adverse decision.

Shareholders who purchased ZVRA stock and experienced financial losses are advised to contact Levi & Korsinsky to determine eligibility for potential claims. The firm notes that participation is typically handled on a contingency basis.